RXi completes enrolment in second Phase I trial of anti-scarring drug

Biotechnology company RXi Pharmaceuticals has announced the completion of enrolment in the second Phase I trial of RXI-109, to manage surgical and hypertrophic scars and keloids.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news